Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomized, double-blind, placebo-controlled phase 2 trial

M. R. Rigby; L. A. DiMeglio; M. S. Rendell; E. I. Felner; J. M. Dostou; S. E. Gitelman; C. M. Patel; K. J. Griffin; E. Tsalikian; P. A. Gottlieb; C. J. Greenbaum; N. A. Sherry; W. V. Moore; R. Monzavi; S. M. Willi; P. Raskin; A. Moran; W. E. Russell; A. Pinckney; L. Keyes-Elstein; M. Howell; S. Aggarwal; N. Lim; D. Phippard; G. T. Nepom; J. McNamara; M. R. Ehlers

doi:10.1089/dia.2015.1510

Back

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomized, double-blind, placebo-controlled phase 2 trial

Annotation

Peer reviewed

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomized, double-blind, placebo-controlled phase 2 trial

M. R. Rigby, L. A. DiMeglio, M. S. Rendell, E. I. Felner, J. M. Dostou, S. E. Gitelman, C. M. Patel, K. J. Griffin, E. Tsalikian, P. A. Gottlieb, …

Diabetes Technology and Therapeutics, Vol.17, pp.S81-S82

17

02/01/2015

DOI: https://doi.org/10.1089/dia.2015.1510

Abstract

Endocrinology, Diabetes and Metabolism

Endocrinology

Medical Laboratory Technology

Metrics

5 Record Views

Details

Title: Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study)
Creators: M. R. Rigby (Author) - Riley Hospital for Children
L. A. DiMeglio (Author) - Indiana University-Purdue University Indianapolis
M. S. Rendell (Author) - Department of Medicine
E. I. Felner (Author) - Emory University
J. M. Dostou (Author) - University of North Carolina
S. E. Gitelman (Author) - University of California at San Francisco
C. M. Patel (Author) - University of Arizona
K. J. Griffin (Author) - University of Arizona
E. Tsalikian (Author) - University of Iowa
P. A. Gottlieb (Author) - University of Colorado Denver
C. J. Greenbaum (Author) - Virginia Mason Medical Center
N. A. Sherry (Author) - Harvard University
W. V. Moore (Author) - Children's Mercy Hospitals and Clinics
R. Monzavi (Author) - University of Southern California
S. M. Willi (Author) - University of Pennsylvania
P. Raskin (Author) - University of Texas at Dallas
A. Moran (Author) - University of Minnesota Twin Cities
W. E. Russell (Author) - Vanderbilt University
A. Pinckney (Author) - Rho Federal Systems Division, Inc.
L. Keyes-Elstein (Author) - Immune Tolerance Network
M. Howell (Author) - Immune Tolerance Network
S. Aggarwal (Author) - Immune Tolerance Network
N. Lim (Author) - Immune Tolerance Network
D. Phippard (Author) - Immune Tolerance Network
G. T. Nepom (Author) - Virginia Mason Medical Center
J. McNamara (Author) - National Institutes of Health
M. R. Ehlers (Author) - Immune Tolerance Network
Additional links: Clark, Terry D.; Potter, Joshua D.; Larson, Jennifer M.; Mordeson, John N.; Wierman, Mark J.; Caulfield, J.H.; Chen, S.H.; Cheng, H.D.; Duro, R.; Caufield, J.H.; Chen, S.H.; Cheng, H.D.; Duro, R.; Honavar, V.
Publication Details: Diabetes Technology and Therapeutics, Vol.17, pp.S81-S82
Series: 17
Identifiers: 991005930588702656
Academic Unit: General Medicine
Language: English
Resource Type: Annotation

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomized, double-blind, placebo-controlled phase 2 trial

Abstract

Related links

Metrics

Details